OncoMatch/Clinical Trials/NCT06090539
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Is NCT06090539 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including BMS-986458 and Rituximab for relapsed/refractory non-hodgkin lymphoma.
Treatment: BMS-986458 · Rituximab · Glofitamab/Obinutuzumab · Mosunetuzumab — The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6 (BCL6), as a single agent and in combination with anti-lymphoma agents in participants with relapsed/refractory non-Hodgkin Lymphoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Allowed: BCL2 rearrangement
Allowed: MYC rearrangement
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: combination chemotherapy (rituximab, anthracycline, alkylating agent, steroids) — first-line
first-line combination chemotherapy regimen containing rituximab, anthracycline, an alkylating agent, and steroids
Cannot have received: CAR-T cell therapy
Participants must not have prior CAR-T
Cannot have received: radiotherapy
radiotherapy ≤ 4 weeks
Cannot have received: systemic anticancer treatment
systemic anticancer treatment ≤ 5 half-lives or 4 weeks
Cannot have received: allogeneic stem cell transplant
Exception: only applicable to BMS-986458 single agent or rituximab combination cohorts
allogeneic SCT ≤ 6 months (only applicable to BMS-986458 single agent or rituximab combination cohorts)
Cannot have received: autologous stem cell transplant
autologous SCT ≤ 3 months prior to study intervention initiation
Cannot have received: solid organ transplantation
Exception: only in BMS-986458 + T-cell engager combination cohorts
Participants must not have prior alloSCT or solid organ transplantation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic in Arizona - Phoenix · Phoenix, Arizona
- City of Hope Comprehensive Cancer Center · Duarte, California
- Local Institution - 0068 · Jacksonville, Florida
- Local Institution - 0027 · Tampa, Florida
- Local Institution - 0014 · Fairway, Kansas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06090539 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CAR-T cell therapy, radiotherapy, systemic anticancer treatment disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages